United States · Research & regulatory guide
Connecting with physicians online: research, content and US advertising rules
A physician may arrive through a search result, read a product page and return through an email. Plan those encounters as one information journey, while reviewing each promotional message on its own terms. Historical research offers a useful starting question: does the content help the clinician find and evaluate the information they need?
About the historical material and this article
A Google-hosted copy of the 2009 research was located and reviewed. This is a new editorial article, not a reproduction of the webinar or a claim that the research file is identical to the former FDASM download.
Former resource: Connecting with Physicians Online Webinar Deck
This article focuses on US federal sources. The linked frameworks retain their state-specific and product-specific limits. It provides general orientation, not campaign clearance or FDA endorsement.
What the original research can tell us
Historical research
Google announced the ThinkHealth webinar for 5 November 2009. The associated Google/Hall & Partners research examined physicians’ internet use and search behaviour in clinical work. Its methodology slide describes an online survey and embedded search exercises with 411 US physicians across primary care, endocrinology, cardiology and psychiatry, fielded from 20 May to 8 June 2009.
A later slide reports that 86% had used the internet for health, medical or prescription-drug information, but gives a base of 458 and an August 2009 source label. Preserve that difference: the percentage should not be described as a finding from the 411-person exercise. This dated study is not a current estimate of all physicians’ behaviour.
For a present-day project, use the research as a prompt to investigate your own audience. Ask what question brings a clinician to the page, which evidence they need and how they recognise the information’s origin. Validate those assumptions with current user research instead of turning a historical statistic into a campaign promise.
Choose the communication route before writing
Editorial workflow
Write a one-sentence purpose for each asset: a product advertisement, a general disease explanation, an answer to a medical enquiry or a scientific communication. Record the sender, intended readers and distribution method. A physician portal, a public landing page and a sponsored search result can expose the same material in different contexts.
For prescription-drug advertising, 21 CFR 202.1 addresses misleading claims and the balance of effectiveness and risk information. Review the actual advertised use and its support before choosing the headline. Use the prescription-medicine framework for a drug; a device requires its own classification and advertising analysis.
Sources: [3]
Review the search result and landing page together
Draft guidance and editorial application
The FDA character-space draft recommends including benefits and risks in the same short product message and reconsidering formats that cannot accommodate them. It remains a draft, not for implementation. Treat its examples as a review aid alongside applicable requirements, rather than assuming a link to the full page solves every short-ad problem.
As an editorial exercise, place the search creative next to a mobile screenshot of its destination. Check whether both identify the same product, population and purpose. Mark every statement that depends on a qualification elsewhere. Then decide whether to change the claim, use a different format or abandon that particular execution.
Sources: [4]
Make follow-up email part of the review
Regulator guidance and editorial application
The FTC explains that CAN-SPAM covers commercial business-to-business email. Its checklist includes truthful sender and subject information, applicable advertising identification, a postal address and a working opt-out; opt-outs must be honoured within ten business days. A professional recipient list is not a general exemption.
For a webinar follow-up, review the invitation, subject line, summary and destination as separate assets. Keep the promised educational topic consistent with the material delivered. Record which team manages suppression requests and which team approves product statements. Moving the conversation into email should not erase the earlier review decisions.
Sources: [5]
Give scientific discussion a separate assessment
Guidance status
FDA’s January 2025 SIUU guidance concerns certain firm-initiated scientific communications about unapproved uses to prescribing or administering healthcare professionals. Its official page labels it final but also says it is not for current implementation pending an OMB decision. That implementation caveat matters when considering the document as a basis for action.
As a practical hand-off, identify the scientific question, the intended recipients, the proposed source publication and the commercial context. Ask the medical and regulatory reviewers to determine the appropriate route. Do not assume that attaching a journal article or using a professional login resolves the classification.
Sources: [6]
Review checklist
Editorial recommendation
- Define the clinical information task and intended audience.
- Record product classification and the purpose of every asset.
- Review the short message, full page and email in their actual layouts.
- Attach evidence and a reviewer decision to each proposed claim.
- Recheck source status when the campaign or guidance changes.
Sources and status
Historical records establish context. Regulatory records support the scoped discussion above; draft recommendations and implementation limits are identified separately. Source dates and verification limits are retained below.
- Google Partners Blog — Upcoming webinars to get you thinking
Historical announcement — 23 October 2009
Relevant passage: ThinkHealth with Google — Connecting with Physicians Online
- Connecting with Physicians Online: Searching for Answers
Historical study — November 2009
Relevant passage: Printed slides 3–4 and 11; PDF pages 4–5 and 12
The methodology reports 411 participants; the 86% chart reports a base of 458. Do not combine these denominators. Exact identity with the former FDASM file is unconfirmed.
- 21 CFR 202.1 — Prescription-drug advertisements
Relevant passage: Paragraphs (a), (e)(1), (e)(2), (e)(4) and (e)(5)
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- FDA — Internet/Social Media Platforms with Character Space Limitations
Draft guidance — not for implementation
Relevant passage: Sections III–V; especially benefit and risk in each communication
Nonbinding draft recommendations, not a new exemption from advertising requirements. Status checked on the official record.
- CAN-SPAM Act: A Compliance Guide for Business
Relevant passage: Commercial email requirements and opt-out deadlines
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- FDA — Scientific Information on Unapproved Uses communicated to HCPs
Final guidance — not for current implementation pending OMB decision
Relevant passage: Guidance scope and OMB information-collection statement
The official record still states not for current implementation. Do not present the final label as unconditional permission to promote unapproved uses.